Overview

BAY94-9027 PK Study Comparing to Another Long Acting Product

Status:
Completed
Trial end date:
2018-09-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the pharmacokinetics of BAY94-9027 and Elocta after intravenous administration.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Factor VIII